Agenus Inc. AJ81.F Stock
Agenus Inc. Price Chart
Agenus Inc. AJ81.F Financial and Trading Overview
Agenus Inc. stock price | 0.39 EUR |
Previous Close | 1.6 EUR |
Open | 1.61 EUR |
Bid | 1.6 EUR x 87500 |
Ask | 1.7 EUR x 84100 |
Day's Range | 1.61 - 1.61 EUR |
52 Week Range | 1.14 - 3.1 EUR |
Volume | 800 EUR |
Avg. Volume | 52 EUR |
Market Cap | 583.28M EUR |
Beta (5Y Monthly) | 1.417311 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10 EUR |
AJ81.F Valuation Measures
Enterprise Value | 522.85M EUR |
Trailing P/E | N/A |
Forward P/E | -1.656701 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 6.1407585 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 5.505 |
Enterprise Value/EBITDA | -2.735 |
Trading Information
Agenus Inc. Stock Price History
Beta (5Y Monthly) | 1.417311 |
52-Week Change | 25.81% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.1 EUR |
52 Week Low | 1.14 EUR |
50-Day Moving Average | 1.38 EUR |
200-Day Moving Average | 2.08 EUR |
AJ81.F Share Statistics
Avg. Volume (3 month) | 52 EUR |
Avg. Daily Volume (10-Days) | 80 EUR |
Shares Outstanding | 348.88M |
Float | 290.62M |
Short Ratio | N/A |
% Held by Insiders | 8.21% |
% Held by Institutions | 59.51% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -252.67% |
Operating Margin (ttm) | -209.49% |
Gross Margin | 66.47% |
EBITDA Margin | -201.23% |
Management Effectiveness
Return on Assets (ttm) | -29.12% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 94.99M EUR |
Revenue Per Share (ttm) | 0.32 EUR |
Quarterly Revenue Growth (yoy) | -11.70% |
Gross Profit (ttm) | 82.61M EUR |
EBITDA | -191144000 EUR |
Net Income Avi to Common (ttm) | -240215008 EUR |
Diluted EPS (ttm) | -0.79 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 189.23M EUR |
Total Cash Per Share (mrq) | 0.54 EUR |
Total Debt (mrq) | 87.75M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.077 |
Book Value Per Share (mrq) | -0.171 |
Cash Flow Statement
Operating Cash Flow (ttm) | -181508000 EUR |
Levered Free Cash Flow (ttm) | -143887008 EUR |
Profile of Agenus Inc.
Country | Germany |
State | MA |
City | Lexington |
Address | 3 Forbes Road |
ZIP | 02421-7305 |
Phone | 781 674 4400 |
Website | https://www.agenusbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 533 |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Q&A For Agenus Inc. Stock
What is a current AJ81.F stock price?
Agenus Inc. AJ81.F stock price today per share is 0.39 EUR.
How to purchase Agenus Inc. stock?
You can buy AJ81.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Agenus Inc.?
The stock symbol or ticker of Agenus Inc. is AJ81.F.
Which industry does the Agenus Inc. company belong to?
The Agenus Inc. industry is Biotechnology.
How many shares does Agenus Inc. have in circulation?
The max supply of Agenus Inc. shares is 20.95M.
What is Agenus Inc. Price to Earnings Ratio (PE Ratio)?
Agenus Inc. PE Ratio is 0.00000000 now.
What was Agenus Inc. earnings per share over the trailing 12 months (TTM)?
Agenus Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Agenus Inc. company belong to?
The Agenus Inc. sector is Healthcare.